Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

Margaret A. Horn net worth and biography

Margaret Horn Biography and Net Worth

COO of Revolution Medicines

Peg initially studied pharmacy, but shortly into that five-year educational program decided to advance her education by attending either medical or law school. A lawyer-professor at her pharmacy school tailored an independent legal study course for her, sealing her fate. She completed pharmacy school and then studied law at Villanova Law School. While still in law school, she worked part-time in DuPont’s legal department and subsequently joined the company counseling its pharmaceutical division.

Led by an entrepreneurial spirit and a desire to see more of the country, she moved to San Francisco. Once there, she embarked on a 30-year adventure in biotechnology, working at both large/public companies (Genencor International and Kosan Biosciences) and small, privately held companies (Cogentus and ProLynx). Through years of biotech experience including international strategic transactions, worldwide litigation and multiple public and private financings, Peg’s role evolved from counsel to business and operational leadership positions.

Peg holds a B.S. in pharmacy and a J.D., as well as an executive M.B.A. She is a member of the Pennsylvania and California bars and is a registered patent attorney with the U.S. Patent & Trademark Office. She is a registered pharmacist in Pennsylvania.

What is Margaret A. Horn's net worth?: The estimated net worth of Margaret A. Horn is at least $5.02 million as of March 18th, 2024. Ms. Horn owns 139,553 shares of Revolution Medicines stock worth more than $5,018,326 as of April 28th. This net worth approximation does not reflect any other assets that Ms. Horn may own. Additionally, Ms. Horn receives a salary of $775,600.00 as COO at Revolution Medicines. Learn More about Margaret A. Horn's net worth.
How old is Margaret A. Horn?: Ms. Horn is currently 61 years old. There are 5 older executives and no younger executives at Revolution Medicines. The oldest executive at Revolution Medicines is Dr. Stephen M. Kelsey FRC Path., FRCP, M.D., President of Research & Development, who is 63 years old. Learn More on Margaret A. Horn's age.
What is Margaret A. Horn's salary?: As the COO of Revolution Medicines, Inc., Ms. Horn earns $775,600.00 per year. There are 2 executives that earn more than Ms. Horn. The highest earning executive at Revolution Medicines is Dr. Mark A. Goldsmith Ph.D., CEO, President & Chairman, who commands a salary of $1,050,000.00 per year. Learn More on Margaret A. Horn's salary.
How do I contact Margaret A. Horn?: The corporate mailing address for Ms. Horn and other Revolution Medicines executives is 700 Saginaw Drive, Redwood City CA, 94063. Revolution Medicines can also be reached via phone at 650-481-6801 and via email at [email protected]. Learn More on Margaret A. Horn's contact information.
Has Margaret A. Horn been buying or selling shares of Revolution Medicines?: Margaret A. Horn has not been actively trading shares of Revolution Medicines during the last ninety days. Most recently, Margaret A. Horn sold 2,914 shares of the business's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $31.58, for a transaction totalling $92,024.12. Following the completion of the sale, the chief operating officer now directly owns 139,553 shares of the company's stock, valued at $4,407,083.74. Learn More on Margaret A. Horn's trading history.
Who are Revolution Medicines' active insiders?: Revolution Medicines' insider roster includes Jack Anders (Insider), Jeff Cislini (General Counsel), Mark Goldsmith (Insider), Margaret Horn (COO), Stephen Kelsey (President, Research & Development), Lorence Kim (Director), Vincent Miller (Director), Thilo Schroeder (Director), Peter Svennilson (Director), Xiaolin Wang (Insider), and Barbara Weber (Director). Learn More on Revolution Medicines' active insiders.
Are insiders buying or selling shares of Revolution Medicines?: In the last twelve months, insiders at the sold shares 34 times. They sold a total of 236,176 shares worth more than $7,455,013.90. The most recent insider tranaction occured on April, 10th when Director Sushil Patel sold 2,155 shares worth more than $79,735.00. Insiders at Revolution Medicines own 8.5% of the company. Learn More about insider trades at Revolution Medicines.
Information on this page was last updated on 4/10/2024.

Margaret A. Horn Insider Trading History at Revolution Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/18/2024	Sell	2,914	$31.58	$92,024.12	139,553
12/18/2023	Sell	2,993	$25.90	$77,518.70	101,467
12/15/2023	Sell	5,000	$26.64	$133,200.00	104,460
10/16/2023	Sell	25,000	$33.95	$848,750.00	96,960
9/18/2023	Sell	2,514	$31.31	$78,713.34	96,960
9/15/2023	Sell	5,000	$32.08	$160,400.00	99,474
8/31/2023	Sell	10,000	$34.05	$340,500.00	99,474
8/15/2023	Sell	5,000	$30.53	$152,650.00	99,474
3/17/2023	Sell	1,230	$21.78	$26,789.40	100,062
10/31/2022	Sell	17,767	$20.41	$362,624.47	17,767
10/26/2022	Sell	17,768	$20.15	$358,025.20	35,534
3/17/2022	Sell	321	$18.61	$5,973.81
10/2/2020	Sell	70,000	$35.08	$2,455,600.00	10,454

Margaret A. Horn Buying and Selling Activity at Revolution Medicines

Revolution Medicines Company Overview

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Today's Range

Now: $35.96

$34.65

$36.36

50 Day Range

MA: $32.33

$29.05

$37.41

2 Week Range

Now: $35.96

$15.44

$38.73

Volume

1,213,741 shs

Average Volume

1,333,327 shs

Market Capitalization

$5.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.54

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

From Colonial Metals | Ad

See why the elites are pouring billions into gold.

Margaret Horn Biography and Net Worth

What is Margaret A. Horn's net worth?

How old is Margaret A. Horn?

What is Margaret A. Horn's salary?

How do I contact Margaret A. Horn?

Has Margaret A. Horn been buying or selling shares of Revolution Medicines?

Who are Revolution Medicines' active insiders?

Are insiders buying or selling shares of Revolution Medicines?